155 related articles for article (PubMed ID: 26392103)
1. CD30 As a Target for the Treatment of Cutaneous T-Cell Lymphoma.
Prince HM
J Clin Oncol; 2015 Nov; 33(32):3691-6. PubMed ID: 26392103
[TBL] [Abstract][Full Text] [Related]
2. Results of a Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis.
Duvic M; Tetzlaff MT; Gangar P; Clos AL; Sui D; Talpur R
J Clin Oncol; 2015 Nov; 33(32):3759-65. PubMed ID: 26261247
[TBL] [Abstract][Full Text] [Related]
3. Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project.
Kim YH; Tavallaee M; Sundram U; Salva KA; Wood GS; Li S; Rozati S; Nagpal S; Krathen M; Reddy S; Hoppe RT; Nguyen-Lin A; Weng WK; Armstrong R; Pulitzer M; Advani RH; Horwitz SM
J Clin Oncol; 2015 Nov; 33(32):3750-8. PubMed ID: 26195720
[TBL] [Abstract][Full Text] [Related]
4. CD30
Ellis A; Christensen LF; Sharma T; Meyerson H; Kord H; Cooper KD
J Am Acad Dermatol; 2021 Feb; 84(2):530-532. PubMed ID: 32437721
[No Abstract] [Full Text] [Related]
5. Brentuximab as a treatment for CD30+ mycosis fungoides and Sézary syndrome.
Mehra T; Ikenberg K; Moos RM; Benz R; Nair G; Schanz U; Haralambieva E; Hoetzenecker W; Dummer R; French LE; Guenova E; Cozzio A
JAMA Dermatol; 2015 Jan; 151(1):73-7. PubMed ID: 25317818
[TBL] [Abstract][Full Text] [Related]
6. Upregulation of inhibitory signaling receptor programmed death marker-1 (PD-1) in disease evolution from cutaneous lymphoid dyscrasias to mycosis fungoides and Sezary's syndrome.
Nguyen GH; Olson LC; Magro CM
Ann Diagn Pathol; 2017 Jun; 28():54-59. PubMed ID: 28648940
[TBL] [Abstract][Full Text] [Related]
7. Transformation of Sézary syndrome into CD30+ anaplastic large T-cell lymphoma after alemtuzumab therapy with evidence of clonal unity.
Nevet MJ; Zuckerman T; Sahar D; Bergman R
Am J Dermatopathol; 2015 Jan; 37(1):73-7. PubMed ID: 25548993
[TBL] [Abstract][Full Text] [Related]
8. Juvenile mycosis fungoides treated with bexarotene and PUVA.
Rodríguez-Vázquez M; García-Arpa M; González-García J
Int J Dermatol; 2007 Jan; 46(1):99-102. PubMed ID: 17214731
[TBL] [Abstract][Full Text] [Related]
9. Long-term follow-up in 51 patients with mycosis fungoides and Sézary syndrome treated by interferon-alfa.
Jumbou O; N'Guyen JM; Tessier MH; Legoux B; Dréno B
Br J Dermatol; 1999 Mar; 140(3):427-31. PubMed ID: 10233261
[TBL] [Abstract][Full Text] [Related]
10. Sézary Syndrome with Nodal CD30-positive Manifestation Treated with Brentuximab Vedotin and Extracorporeal Photopheresis.
Behle V; von Braunmühl T; Sayehli C; Gesierich A; Goebeler M; Geissinger E; Wobser M
Acta Derm Venereol; 2017 Aug; 97(8):973-975. PubMed ID: 28512672
[No Abstract] [Full Text] [Related]
11. Impressive response of CD30-negative, treatment-refractory mycosis fungoides to brentuximab vedotin.
Goyal A; Hordinsky M; Lazaryan A
Dermatol Ther; 2019 Mar; 32(2):e12835. PubMed ID: 30659762
[TBL] [Abstract][Full Text] [Related]
12. Alitretinoin treatment in mycosis fungoides with CD30-positive large cell transformation.
Park J; Kwon O; Park K; Chung H
Clin Exp Dermatol; 2017 Apr; 42(3):341-342. PubMed ID: 28211143
[No Abstract] [Full Text] [Related]
13. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
[TBL] [Abstract][Full Text] [Related]
14. Tumor-stage mycosis fungoides in palmoplantar localization with large-cell transformation and partial CD30 expression shows complete response to brentuximab vedotin.
Pham AK; Carter JB; Ratcliffe NR; Fuld AD; Lansigan F; Burnside NJ; Guill MA; Zug KA; Jarvis LA; LeBlanc RE
J Cutan Pathol; 2018 Jun; 45(6):458-462. PubMed ID: 29512830
[TBL] [Abstract][Full Text] [Related]
15. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
[TBL] [Abstract][Full Text] [Related]
16. Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Willemze R; Hodak E; Zinzani PL; Specht L; Ladetto M;
Ann Oncol; 2013 Oct; 24 Suppl 6():vi149-54. PubMed ID: 23868906
[No Abstract] [Full Text] [Related]
17. Efficacy of narrowband UVB vs. PUVA in patients with early-stage mycosis fungoides.
Ponte P; Serrão V; Apetato M
J Eur Acad Dermatol Venereol; 2010 Jun; 24(6):716-21. PubMed ID: 19929938
[TBL] [Abstract][Full Text] [Related]
18. Treatment of stage II cutaneous T-cell lymphoma with interferon alfa-2a and extracorporeal photochemotherapy: a prospective controlled trial.
Wollina U; Looks A; Meyer J; Knopf B; Koch HJ; Liebold K; Hipler UC
J Am Acad Dermatol; 2001 Feb; 44(2):253-60. PubMed ID: 11174383
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic reduction of cell-mediated immunosuppression in mycosis fungoides and Sézary syndrome.
Geskin LJ; Akilov OE; Kwon S; Schowalter M; Watkins S; Whiteside TL; Butterfield LH; Falo LD
Cancer Immunol Immunother; 2018 Mar; 67(3):423-434. PubMed ID: 29204699
[TBL] [Abstract][Full Text] [Related]
20. Treatment of CD30-Negative Refractory Mycosis Fungoides With Brentuximab Vedotin.
Zhang C; Chairatchaneeboon M; Haun P; Landsburg D; Kim EJ
JAMA Dermatol; 2018 Jan; 154(1):109-110. PubMed ID: 29167875
[No Abstract] [Full Text] [Related]
[Next] [New Search]
